Market Overview:
A
biopsy is a small operation that is used to perform the removal of tissues from
an area of concern from the body. Breast biopsy
is a medical procedure that involves the testing of small samples of
breast tissues for the detection of breast cancer. This form of biopsy is conducted with the help of minimally invasive biopsy systems due to
minimal pain and disfigurement. There are
various types of biopsy procedures that are used depending upon the different
techniques like vacuum-assisted biopsy (VAB), core
needle biopsy (CNB), and fine needle aspiration biopsy (FNAB). These are recommended by the doctor based on the
size, location, and other characteristics of the breast abnormality.
The global Breast
Biopsy Market Statististis is expected to expand in significant
fashion during the forecast period of 2018 to 2023.
The growing prevalence of breast cancer among women is
the major driver for the global breast imaging
market. Breast cancer is the second most prevalent type
of cancer among women, with more than
200,000 new cases diagnosed every year. Breast cancer has
also become a major public issue in recent
years, with a number of healthcare organizations and
celebrities joining the cause to promote breast
cancer and raise funds for poor patients and further
product development to make breast imaging
easier and more accurate. The growing demand for precise
diagnostic tools that can diagnose breast
cancer at an early stage is likely to be a major driver
for the global breast imaging market over the
forecast period. Early diagnosis of cancer is highly
important in managing the disease and ensuring a
positive prognosis, leading to a growing demand for
product development in the breast imaging market
targeted at developing devices that can detect tumors
when they are at their smallest.
Competitive Landscape
·
Cook
Medical Incorporated
·
Dickinson
and Company
·
NuVue
Therapeutics
·
Argon
Medical Devices
·
Johnson
& Johnson
·
Encapsule
Medical Devices LLC
·
Leica
Biosystems
·
C.R.
Bard Inc
·
Argon
Medical Devices
·
Hologic
Inc
·
Devicor
Medical Products Inc
·
Becton
·
Hologic
Inc
Market Segmentation
·
The
global breast biopsy market segmentation is done
as per technique type, product, guidance technology, and end-user.
·
By
product, the market includes biopsy tables, guidance systems, biopsy needles,
biopsy wires, and others.
·
By
technique type, the market includes core needle biopsy, fine needle aspiration
biopsy, wire localization, MRI-guided core needle biopsy, biopsy markers,
surgical biopsy, and sentinel node biopsy.
·
By
guidance technology, the market includes CT-guided biopsy, ultrasound-guided, mammography-guided magnetic
resonance, and various other image-guided breast
biopsy (PET and thermography).
·
By
end-user, the market comprises of ambulatory surgical centers, hospitals,
diagnostic centers, and others.
Regional Analysis
The
geographical breast biopsy market segmentation covers four major regions,
namely North America, Asia-Pacific, Europe, and the Middle East & Africa.
North America is anticipated to hold the largest market share
over the
forecast period as per the market report published by MRFR. This is primarily due to the early adoption of
advanced medical technologies and a continued
emphasis on the development from
companies operating in cancer diagnostics. The Europe market holds the
second-largest share of the breast biopsy market due to the striking prevalence
of breast cancer in the UK and Belgium. Both North America and Europe comprise
more than 50% of the of the global breast biopsy market share.
The
regional market of Asia-Pacific is also slated to experience a period of growth
in the forthcoming years. This is because
of the demand for advanced technology, better rate of adoption of such
technologies, access to optimal treatment facilities, increasing favorable
initiatives undertaken by the government, and rising healthcare expenditure.
Lastly,
the Middle East & Africa region is expected to garner the least market
growth due to the presence of an underdeveloped
healthcare industry, poor medical facilities, and lack of technical proficiency
and knowledge concerning the operation.
October
30th, 2019, a team from ETH Zurich with support from the Swiss
National Science Foundation developed a new ultrasound method to help
differentiate benign breast tumors from the malignant ones. The clinical trials
have proven to show great promise in the detection of breast cancer and can be
revolutionary in the medical segment for detecting breast cancer.
No comments:
Post a Comment